Navigation Links
Cell Therapy for Cardiovascular Diseases
Date:1/11/2008

The Cardiovascular Research Foundation (CRF) brings experts to New York City from around the world for the Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases. Dedicated to new advances in this emerging field, the three-day session will feature an in-depth review of cell-based therapies for myocardial repair and regeneration, angiogenesis and cutting-edge research findings.

Highlights include:

  • Clinical Focus: Full-day programs for the discussion of heart attacks (ST elevation myocardial infarction, or STEMI) and congestive heart failure (CHF). Each will cover strategies using cell-based therapies to address the chronic ventricular dysfunction underlying these conditions.

  • Cutting Edge Findings including:

    • Work by Dr. Marc Penn and colleagues demonstrating that bone marrow cells can improve heart function soon after a heart attack by saving heart cells that would otherwise die from the attack

    • Research performed by Dr. Gordon M. Keller and colleagues showing for the first time how human embryonic stem cells can be induced into becoming human heart muscle cells, raising new potential for regenerating cardiac muscle after a heart attack

    • First-ever results of work by Dr. A. Terzic and colleagues demonstrating how bone marrow cells can be stimulated into essentially becoming heart muscle cells, something which in recent years had not been thought possible

    • Dr Keith March will present new data showing that 2 special types of cells are necessary to grow new blood vessels, opening up an exciting strategy for the next round of clinical trials

  • Special Sessions on:

    • Cardiac Tissue Engineering, including exciting work in constructing blood vessels and cell sheets of myocardial tissue

    • Angiogenesis, including the use of stem cells derived from bone marrow, adipose, and other sources to synthesize functioning myocardium in patients with heart and peripheral vascular disease

  • Late Breaking Clinical Trials:

    • Long-term results from two major trials (TOPCARE, REPAIR-AMI) of bone-marrow- or blood-derived progenitor cells for acute myocardial infarction will be reviewed by Dr. Andreas M. Zeiher

    • Intravenous allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare

    • MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail here by Dr. Hyo-Soo Kim

    • Data presented by Dr. Hans Dohmann will demonstrate the primary mechanism by which bone marrow cells help patients with acute myocardial infarction

    • Bone marrow-derived stem cells for patients with critical limb ischemia, presented by both Drs. Berthold Amann and Brian Annex

    • Transplantation of bone marrow stem cells for persistent, refractory angina, presented and discussed by Drs. Douglas Losordo and Jorge Tuma

    • CausMic: A randomized, controlled study of myoblasts in patients with heart failure, first reported at AHA 2007, presented in detail here by Dr. Nabil Dib

    • Final 12 month data from the MYOHEART trial in patients with heart failure will be presented for the first time by Dr. Warren Sherman

    • Stem cells in patients with heart failure on left ventricular assist devices, presented by Dr. Eric A. Rose

  • Next-Generation Heart Muscle Cells: Advances in skeletal, myocardial, embryonic, and bone marrow derived techniques

  • A Preview of First-in-Human Studies Planned for the Coming Year

  • MARVEL: the largest randomized placebo-controlled study of skeletal myoblasts in patients with heart failure, presented by Dr. Warren Sherman

  • PRIMO-AMI; a novel bone-marrow derived cell and injection technique in patients with heart attack, presented by Dr. Marc Penn

  • Views of the Future: The last session will 1) present scientific collaborations that will play a major role in stem cell studies, and, 2) offer an extraordinary opportunity for leaders of the field to present their views on future clinical benefits in an open, round-table discussion

WHO:

Hundreds of the worlds leading cell therapy experts will meet to discuss the latest advances in this area.

Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patients own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN:

January 16 18, 2008

WHERE:

Columbia University, Alfred Lerner Hall, 2920 Broadway (at 115th St.), New York, NY


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related biology news :

1. A search for protection against chemotherapy cardiotoxicity
2. Top scientists meet for global conference on stem cell therapy for cardiovascular diseases
3. RNA interference therapy heals growth deficiency disorder in a live animal
4. Safer, more accurate radiation therapy for expecting mothers
5. Cancer and arthritis therapy may be promising treatment for diabetes
6. Dolphin therapy a dangerous fad, Emory researchers warn
7. Ireland Cancer Center researchers advance stem cell gene therapy
8. Safe and effective therapy discovered for patients with protein-losing enteropathy
9. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
10. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
11. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology: